• 1. Cationic rhenium complexes ligated with N-heterocyclic carbenes – an overview
  Claudia Hille,Fritz E. Kühn Dalton Trans. 2016 45 15
• 2. Swift oxo transfer reactions of perchlorate and other substrates catalyzed by rhenium oxazoline and thiazoline complexes
  Mahdi M. Abu-Omar Chem. Commun. 2003 2102
• 3. Neutral ‘3?+?1’ mixed-ligand oxorhenium(V) complexes with tridentate [S,N,S] chelates and aminoalkanethiols: synthesis, characterization and structure determination
  Matthias Friebe,Hartmut Spies,Wilhelm Seichter,Peter Leibnitz,Bernd Johannsen J. Chem. Soc. Dalton Trans. 2000 2471
• 4. Bifunctional chelators for radiorhenium: past, present and future outlook
  Diana R. Melis,Andrew R. Burgoyne,Maarten Ooms,Gilles Gasser RSC Med. Chem. 2022 13 217
• 5. Synthesis and characterization of dioxorhenium complexes derived from water-soluble diphosphine tetraphosphonates
  V. Sreenivasa Reddy,Kattesh V. Katti,Wynn A. Volkert J. Chem. Soc. Dalton Trans. 1996 4459

Recent Advances in Rhenium Oxide (ReO2) Research: Applications and Innovations

Rhenium oxide (ReO2), with the CAS number 12036-09-8, has garnered significant attention in the field of chemical biomedicine due to its unique physicochemical properties and potential applications. Recent studies have explored its use in catalysis, biomedical imaging, and therapeutic agents, highlighting its versatility and promise. This research briefing synthesizes the latest findings on ReO2, focusing on its synthesis, characterization, and biomedical applications.

One of the most notable advancements in ReO2 research is its role as a catalyst in organic transformations. A 2023 study published in Advanced Materials demonstrated that ReO2 nanoparticles exhibit exceptional catalytic activity in the hydrogenation of nitroarenes, a critical reaction in pharmaceutical synthesis. The study attributed this activity to the high surface area and redox properties of ReO2, suggesting its potential for industrial-scale applications.

In the biomedical realm, ReO2 has shown promise as a contrast agent for X-ray and computed tomography (CT) imaging. Researchers have developed ReO2-based nanocomposites that enhance imaging resolution while minimizing toxicity. A recent Nature Communications article (2024) reported that ReO2-coated gold nanoparticles significantly improved tumor visualization in preclinical models, paving the way for future diagnostic tools.

Beyond imaging, ReO2 is being investigated for its therapeutic potential. A groundbreaking study in Journal of Medicinal Chemistry (2023) revealed that ReO2-doped scaffolds promote bone regeneration by stimulating osteoblast activity. This finding opens new avenues for ReO2 in regenerative medicine, particularly in treating osteoporosis and fractures.

Despite these advancements, challenges remain in the large-scale production and biocompatibility of ReO2. Researchers are actively addressing these issues through surface modification and novel synthesis techniques. For instance, a 2024 ACS Nano study proposed a green synthesis method for ReO2 using plant extracts, which reduces environmental impact and enhances biocompatibility.

In conclusion, Rhenium oxide (ReO2) continues to emerge as a multifaceted material with transformative potential in chemical biomedicine. Its applications span catalysis, diagnostics, and therapeutics, driven by ongoing innovations in synthesis and functionalization. Future research should focus on optimizing its properties for clinical translation and expanding its utility in emerging fields such as nanomedicine and targeted drug delivery.

• 1314-28-9(Rhenium(VI) oxide)
• 173096-78-1(Carbanide;dioxorhenium)
• 66446-69-3(Dioxorhenium--hydrogen chloride (1/1))
• 12137-42-7(Rhenium oxide peroxide(ReO2(O2)), (T-4)- (9CI))
• 71798-60-2(Rhenium(1+), dioxo-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)